Clinical Trials
- Headaches
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)
- Ages6 years - 17 years
- GenderBoth
- Brain, Spinal Cord & Nervous System, Mental Health & Behavioral Research
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures
- Ages18 years - 70 years
- GenderBoth
A Global Real-World Study to Assess HyQvia Use and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Switching to HyQvia
A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions
- Brain and Other Nervous System Cancers, Leukemia, Lymphoma
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
- Ages18 years and older
- GenderBoth
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy
- Ages18 years - 75 years
- GenderBoth
- Brain and Other Nervous System Cancers
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Glioma
- Brain, Spinal Cord & Nervous System
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Heart/Cardiovascular
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)
- Ages30 years and older
- GenderBoth
- Brain and Other Nervous System Cancers
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma